For tumors reported with clinical response to the anti-PD-1/PD-L1 therapies including melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) and bladder cancer, the range of PD-L1 expression falls from 14% to 100% [11,12,13]. This evidence concerns the gene CD274 and renal cell carcinoma.